External Quality Assurance (QA)

for

Neonatal G6PD Screening


G6PD QA MIS System [login]

External Quality Assurance for Neonatal G6PD Screening Schedule for 2010

[Chinese Version]


Introduction¡G

¡@¡@Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49) deficiency is the most common enzymopathic disease in Southeast Asia and other tropical areas worldwide. This X-linked genetic disorder (MIM 305900) has been found to be an important cause of neonatal jaundice and acute haemolytic anemia in the southern Chinese population in Taiwan.  In order to reduce the complications of G6PD deficiency, such as kernicterus, permanent neurological damage and death, nationwide neonatal screening for G6PD deficiency was started on 1 July 1987 after a pilot project conducted between November 1984 and June 1987 had demonstrated the practicality and the efficiency of neonatal screening of G6PD deficiency in Taiwan.  The effective collection rate has reached more than 99% of all newborns in Taiwan since 1996 and the overall incidence rate of G6PD deficiency was found to be about 2%.  To assess the reliability and to improve the quality of the screening tests performed by each neonatal screening center, an external quality assurance (EQA) program for determination for blood G6PD activity was developed since 1999.

        Periodically, 10 QC specimens were randomly picked for each survey and distributed to each neonatal screening laboratory by speed post delivery.  Reports were requested to be returned by facsimile (and internet submission since 2005) within 4 days for screening centers in Taiwan and 8 days for overseas screening centers.  For each QA survey, the G6PD activity of the QC dried blood spots was determined by quantitative assay13 to set the reference values before the QC specimens were send out.  The results reported by the screening centers were evaluated against the consensus result and compared with the quantitative reference values determined by our laboratory.  The summary report for each survey was published on website within two weeks after the survey started.  

Participating Laboratories

  • Australia
  • [SA Neonatal Screening Laboratory-Australia]
  • China (Mainland)
  • [Foshan Neonatal Screening Center-Foshan] [Fujian Neonatal Screening Center-Fujian] [Guangzhou Neonatal Center-Guangzhou] [Shanghai Children's Hospital-Shanghai] [Shanghai Neonatal Screening Center-Shanghai] [Shenzhen Neonatal Screening Center-Shenzhen] [Xiamen's Maternal & Child Health Care Hospital] [Zhanjiang Neonatal Screening Center-Zhangjiang][Zhongshan Neonatal Screening Center-Zhongshan]

  • Finland
  • [Ani Labsystems Ltd-Finland] [PerkinElmer Wallac Inc-Finland]
  • Germany
  • [Screening-Labor Hannover- Germany] [Screening-Zentrum Hessen- Germany]
  • India
  • [Department of Genetics, Dr Lal PathLabs]
  • Lebanon
  • [Faculty of Medicne-USJ-Lebanon]
  • Philippines
  • [National Institutes of Health-Philippines] [Newborn Screening Center Visayas-Philippines] [Newborn Screening Center-Mindanao]
  • Taiwan
  • [CFOH-Taipei] [NTU Hospital-Taipei] [TIP-Taipei]
  • Thailand
  • [Queen Sirikit National Institute of Child Health-Thailand]
  • Turkey
  • [Tanyalcin Tip Laboratory-Turkey]
  • Vietnam
  • [Tu Du Hospital-Vietnam]

    External Quality Assurance for Neonatal G6PD Screening :

    January 2010~

    ¡@¡@¡@¡@  1. Survey No : NS2010-01

    ¡@¡@¡@¡@  2. Survey No : NS2010-03

    ¡@¡@¡@¡@  3. Survey No : NS2010-05

    ¡@¡@¡@¡@  4. Survey No : NS2010-07

    January 2009~December 2009

    January 2008~December 2008

    January 2007~December 2007

    January 2006~December 2006

    January 2005~December 2005

    January 2004~December 2004

    January 2003~December 2003

    January 2002~December 2002

    January 2001~December 2001

    July 1999~Dec 2000

    July 1998~June 1999

    Publication List of G6PD QA


    Preventive Medicine Foundation
    Address : Peitou P.O. Box 2-182 Taipei, Taiwan, 11299
    TEL : +886-2-2871-7718 ; Fax : +886-2-2872-7714
    E-mail :

    updated : 16 Jul, 2010


    HOME